ARS Pharmaceuticals (SPRY) Operating Leases (2020 - 2025)

ARS Pharmaceuticals has reported Operating Leases for 5 years, with the latest figure at $949000.0 in Q3 2025.

• Quarterly Operating Leases changed N/A year-over-year to $949000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $949000.0 (changed N/A YoY) and the FY2023 annual result came in at $37000.0, down 85.26% from the prior year.
• Operating Leases eased to $949000.0 in Q3 2025 per SPRY's latest filing, from $1.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $5.1 million in Q3 2021 and troughed at $37000.0 in Q4 2023.
• A 4-year average of $1.7 million and a median of $949000.0 in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases surged 128.63% in 2022, then sank 96.41% in 2023.
• Over 4 years, Operating Leases stood at $480000.0 in 2021, then sank by 47.71% to $251000.0 in 2022, then sank by 85.26% to $37000.0 in 2023, then soared by 2464.86% to $949000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $949000.0, $1.1 million, and $37000.0 for Q3 2025, Q2 2025, and Q4 2023 respectively.